miR-145和miR-93对泌乳素腺瘤耐药的研究进展  

Research progress on the resistance of miR-145 and miR-93 to prolactinoma

作　　者：李家琪 史信康 周满鑫 唐涛 叶锋[2] LI Jiaqi;SHI Xinkang;ZHOU Manxin;TANG Tao;YE Feng(School of Medical and Life Sciences,Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan 611137,China;Department of Neurosurgery,Deyang People's Hospital,Deyang,Sichuan 618000,China;Clinical Medicine School of North Sichuan Medical College,Nanchong,Sichuan 637000,China;Clinical Medicine School of Chengdu Medical College,Chengdu,Sichuan 610500,China)

机构地区：[1]成都中医药大学医学与生命科学学院,四川成都611137 [2]德阳市人民医院神经外科,四川德阳618000 [3]川北医学院临床医学院,四川南充637000 [4]成都医学院临床医学院,四川成都610500

出　　处：《医药前沿》2024年第4期39-41,共3页Journal of Frontiers of Medicine

摘　　要：泌乳素腺瘤是最常见的功能性垂体肿瘤,临床表现为高催乳素血症、肿瘤局部压迫症状、垂体卒中、多激素混合腺瘤.目前指南推荐,多巴胺激动剂(DA)是首选治疗药物,有效率为67%,但约20%的垂体泌乳素瘤会出现耐药现象.微小核糖核酸(miRNA)参与肿瘤的发生发展、侵袭以及药物抵抗等过程.近年来,miRNA在耐药溴隐亭催乳素瘤中的表达知之甚少.本文系统阐述miRNA的生物学特征、生物学功能以及CircOMA1-miR-145-5P-TPT_(1)轴和lncRNA H19-miR-93-ATG7轴在垂体腺瘤中耐药的调控网络,为基础研究及临床提供参考.Prolactinoma is the most common functional pituitary tumor,characterized by hyperprolactinemia,local tumor compression symptoms,pituitary stroke,and multi-hormone mixed adenoma.Currently,guidelines recommend dopamine agonists(DA)as the preferred treatment drug,with an effective rate of about 67%,but about 20%of pituitary prolactinomas may exhibit drug resistance.MicroRNAs(miRNA)are involved in the occurrence,development,invasion,and drug resistance of tumors.In recent years,little is known about the expression of miRNA in bromocriptin resistant prolactinomas.Therefore,this article systematically elaborates on the biological characteristics and functions of miRNA,as well as the regulatory network of circOMA1-miR-145-5P-TPT_(1) axis and lncRNA H19-miR-93-ATG7 axis in drug resistance in pituitary adenomas,providing reference for basic research and clinical practice.

关 键 词：垂体神经内分泌肿瘤 多巴胺受体激动剂 耐药性 miR-93 MIR-145 

分 类 号：R651.1[医药卫生—外科学]